Achondroplasia
- PMID: 18328977
- DOI: 10.1016/j.berh.2007.12.008
Achondroplasia
Abstract
Achondroplasia (MIM 100800) is the most common non-lethal skeletal dysplasia. Its incidence is between one in 10,000 and one in 30,000. The phenotype is characterized by rhizomelic disproportionate short stature, enlarged head, midface hypoplasia, short hands and lordotic lumbar spine, associated with normal cognitive development. This autosomal-dominant disorder is caused by a gain-of-function mutation in the gene encoding the type 3 receptor for fibroblast growth factor (FGFR3); in more than 95% of cases, the mutation is G380R. The diagnosis is suspected on physical examination and confirmed by different age-related radiological features. Anticipatory and management care by a multidisciplinary team will prevent and treat complications, including cervical cord compression, conductive hearing loss and thoracolumbar gibbosity. Weight counselling, psychosocial guidance and professional integration programmes play an important role in the global quality of life of these patients and their families.
Similar articles
-
[Mutations in the Fibroblast Growth Factor Receptor 3 gene (FGFR3) in Chilean patients with idiopathic short stature, hypochondroplasia and achondroplasia].Rev Med Chil. 2003 Dec;131(12):1405-10. Rev Med Chil. 2003. PMID: 15022403 Spanish.
-
Clinical and molecular characteristics of Thai patients with achondroplasia.Southeast Asian J Trop Med Public Health. 2001 Jun;32(2):429-33. Southeast Asian J Trop Med Public Health. 2001. PMID: 11556601
-
A common FGFR3 gene mutation is present in achondroplasia but not in hypochondroplasia.Am J Med Genet. 1995 Jan 2;55(1):127-33. doi: 10.1002/ajmg.1320550132. Am J Med Genet. 1995. PMID: 7702086
-
Achondroplasia: Current Options and Future Perspective.Pediatr Endocrinol Rev. 2015 Jun;12(4):388-95. Pediatr Endocrinol Rev. 2015. PMID: 26182483 Review.
-
Advances in understanding etiology of achondroplasia and review of management.Curr Opin Pediatr. 2007 Feb;19(1):32-7. doi: 10.1097/MOP.0b013e328013e3d9. Curr Opin Pediatr. 2007. PMID: 17224659 Review.
Cited by
-
Vosoritide, a miracle drug, covering unmet need in achondroplasia: A regulatory update.Intractable Rare Dis Res. 2023 Nov;12(4):257-261. doi: 10.5582/irdr.2023.01055. Intractable Rare Dis Res. 2023. PMID: 38024582 Free PMC article.
-
Gait in children with achondroplasia - a cross-sectional study on joint kinematics and kinetics.BMC Musculoskelet Disord. 2022 Apr 28;23(1):397. doi: 10.1186/s12891-022-05343-4. BMC Musculoskelet Disord. 2022. PMID: 35484571 Free PMC article.
-
Paleopathological Study of Dwarfism-Related Skeletal Dysplasia in a Late Joseon Dynasty (South Korean) Population.PLoS One. 2015 Oct 21;10(10):e0140901. doi: 10.1371/journal.pone.0140901. eCollection 2015. PLoS One. 2015. PMID: 26488291 Free PMC article.
-
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial.EClinicalMedicine. 2023 Oct 2;65:102258. doi: 10.1016/j.eclinm.2023.102258. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37823031 Free PMC article.
-
Neonatal Bone Disorders.Front Pediatr. 2021 Apr 6;9:602552. doi: 10.3389/fped.2021.602552. eCollection 2021. Front Pediatr. 2021. PMID: 33889553 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources